Novo spends €10bn to make more Wegovy weight loss drugs

The deal for Catalent has the backing of Elliott Investment Management, the activist investor, which has a stake in the US company

The new plants Novo Nordisk is buying to manufacture its Wegovy weight loss drug
are located in Indiana, Italy, and Belgium.

Novo Nordisk has agreed to buy three manufacturing plants for €10bn to help it meet surging demand for its obesity treatments.

Novo is buying the fill-finish sites from its main shareholder, Novo Holdings, which agreed to buy the owner of the assets, Catalent, in a deal with an enterprise value of around €15.3bn.